Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer combo trial halted early: what we know

NCT ID NCT04524689

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tested a new drug (tusamitamab ravtansine) combined with pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a marker called CEACAM5. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU BREST 5 Avenue Foch_Investigational Site Number :2500003

    Brest, 29200, France

  • Centre François Magendie Hôpital du Haut Lévèque Av.de Magellan_Investigational Site Number :2500001

    Pessac, 33600, France

  • Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005

    Temuco, La Araucanía, 4780000, Chile

  • Fakultní nemocnice Olomouc Onkologická klinika I.P. Pavlova 6_Site Number :2030001

    Olomouc, 77900, Czechia

  • ICEGCLINIC Avenida Serafín Zamora 190 Torre B, piso 4. La Florida_Investigational Site Number :1520006

    Santiago, 8241470, Chile

  • Institut Sainte-Catherine 250 Chemin de Baigne-Pieds_Investigational Site Number :2500005

    Avignon, 84918, France

  • Investigational Site Number : 3760001

    Ramat Gan, 5266202, Israel

  • Investigational Site Number : 3760002

    Tel Aviv, 64239, Israel

  • Investigational Site Number : 7240001

    Madrid, 28041, Spain

  • Investigational Site Number : 7240002

    Las Palmas, 35016, Spain

  • Investigational Site Number : 7240004

    Madrid, 28040, Spain

  • Investigational Site Number : 7240005

    A Coruña, A Coruña [La Coruña], 15006, Spain

  • Investigational Site Number : 7240006

    Badalona, Catalunya [Cataluña], 08916, Spain

  • Investigational Site Number : 7240007

    Oviedo, Principality of Asturias, 33011, Spain

  • KU Medical Center_Investigational Site Number :8400002

    Westwood, Kansas, 66205, United States

  • Nemocnice AGEL Ostrava - Vitkovice Plicní oddělení Zalužanského 2214/35_Site Number :2030002

    Ostrava - Vitkovice, 70384, Czechia

  • ONCOCENTRO APYS Av. La Marina 1702, 2do piso, Viña del Mar_Investigational Site Number :1520003

    Viña del Mar, Valparaiso, 2520598, Chile

  • Orlandi Oncologia General Salvo 159, Providencia_Investigational Site Number :1520002

    Santiago, 7500713, Chile

  • Országos Onkológiai Intézet Ráth György u. 7_Investigational Site Number :3480002

    Budapest, 1122, Hungary

  • Pôle régional de Cancérologie 2 rue de la Milèterie BP 577_Investigational Site Number :2500004

    Poitiers, 86021, France

  • Veszprém Megyei Tüdőgyógyintézet 049/2 Hrsz_Investigational Site Number :3480004

    Farkasgyepü, 8582, Hungary

Conditions

Explore the condition pages connected to this study.

NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC)